Editorial: Drug discovery for leishmaniasis and chagas disease: compound design and therapeutic strategies
Abstract
target deconvolution, host-directed and delivery innovations, and, where appropriate, resistance-aware combinations. Five articles were accepted; all focused on Leishmania biology and therapy. While no Chagas disease studies were included, several mechanistic and translational insights are likely applicable to T. cruzi, particularly where pathogen pathways or host responses are conserved.The articles in this Topic collectively map a coherent arc for antileishmanial drug discovery: from how we prioritise hits and leads to how we think about pharmacology, resistance, and the host response. Taken together, they delineate common scientific threads with direct implications for the next wave of candidates.A first theme is the re-emergence of N-myristoyltransferase (NMT) as a compelling antileishmanial target, approached from distinct starting points. Boudou Furthermore, shorter or reduced-dose regimens were well tolerated and could substantially improve treatment tolerability and accessibility. However, the authors emphasize that further studies are needed to confirm these results.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.